Back to Browse Journals » Drug Design, Development and Therapy » Volume 2

Development and targeted use of nilotinib in chronic myeloid leukemia

Authors Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Published Date November 2008 Volume 2008:2 Pages 233—243

DOI http://dx.doi.org/10.2147/DDDT.S3181

Published 10 November 2008

Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Abstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired resistance has been traced to Bcr-Abl kinase domain mutations. Several strategies have been developed to overcome the problem of imatinib resistance, including imatinib dose escalation, novel targeted agents and combination treatments. A second generation of tyrosine kinase inhibitors was developed, which displays increased potency towards Bcr-Abl and is able to target the majority of CML mutant clones. Nilotinib (Tasigna®, AMN107, Novartis) is a close analog of imatinib with approximately 20-fold higher potency for BCR-ABL kinase inhibition. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure, with a good tolerance. Nilotinib has been approved for CML patients in chronic and accelerated phases, post imatinib failure.

Keywords: nilotinib, imatinib-resistance, imatinib-intolerance, CML

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Core Evidence 2009, 4:207-213

Published Date: 5 October 2009

Readers of this article also read:

A safety-modified SV40 Tag developed for human cancer immunotherapy

Stephanie S Tseng-Rogenski, Mohamed S Arredouani, June F Escara-Wilke, Yilin C Neeley, Michael J Imperiale et al

Drug Design, Development and Therapy 2008, 2:17-24

Published Date: 8 January 2008

Outcome of anthroposophic medication therapy in chronic disease: A 12-month prospective cohort study

Harald J Hamre, Claudia M Witt, Anja Glockmann, Renatus Ziegler, Gunver S Kienle et al

Drug Design, Development and Therapy 2008, 2:25-37

Published Date: 8 January 2008

Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations

Akira Fujii, Norio Yasui-Furukori, Taku Nakagami, Takenori Niioka, Manabu Saito, et al

Drug Design, Development and Therapy 2008, 2:139-144

Published Date: 11 August 2008

Structure-based design of anticancer prodrug PABA/NO

Xinhua Ji, Ajai Pal, Ravi Kalathur, Xun Hu, Yijun Gu, et al

Drug Design, Development and Therapy 2008, 2:123-130

Published Date: 11 August 2008

Does wine prevent dementia?

Roger M Pinder

International Journal of Wine Research 2009, 1:41-52

Published Date: 4 February 2009

Epigenomics in cancer management

Fabricio F Costa

Cancer Management and Research 2010, 2:255-265

Published Date: 27 October 2010

An analysis of the Bateson Review of research using nonhuman primates

Greek R, Hansen LA, Menache A

Medicolegal and Bioethics 2011, 1:3-22

Published Date: 6 December 2011

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012